
This version is available at https://strathprints.strath.ac.uk/65804/

Strathprints is designed to allow users to access the research output of the University of Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Please check the manuscript for details of any other licences that may have been applied. You may not engage in further distribution of the material for any profitmaking activities or any commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the content of this paper for research or private study, educational, or not-for-profit purposes without prior permission or charge.

Any correspondence concerning this service should be sent to the Strathprints administrator: strathprints@strath.ac.uk
Drug to Patient
Pharmaceutical and Scientific Collaboration

Gavin Halbert
Cancer Research UK Formulation Unit
Strathclyde Institute of Pharmacy and Biomedical Sciences
University of Strathclyde
Formulation Unit

- Established in 1983 – unique within UK
  Based on under-graduate pharmacy teaching
- Develop novel anti-cancer drugs selected by Cancer Research UK
- Antibodies – Alkylating Agents – Antisense
- Drug Delivery Systems
  - Liposomes
  - ADEPT
Collaboration

Bench
- Chemistry
- Formulation
- Pharmacology
- Physical

Pharmaceutical Translation
- Scale Up
- Manufacture
- Stability
- Packaging
- Distribution
- Regulatory

Bedside
- ECMC
- Pharmacists
- Oncologists
- Patient

Broad spectrum of blue sky and applied science

Appropriate pharmaceutical knowledge at all stages
Cancer survival in the UK has doubled in the last 40 years.

This is successful

temozolomide

abiraterone acetate
Thank you

• Funder – Cancer Research UK

• Collaborators
  Many and varied
  Local, national and international

• Organisers - Invitation

• You for listening